Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RBP4 | P02753 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24139778 | 0.90 | HSD11B1 (0.68) | HSD11B1ALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL19149697 | 0.87 | HSD11B1 (0.64) | HSD11B1ALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL24273866 | 0.86 | HSD11B1 (0.67) | HSD11B1ALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL5564147 | 0.86 | HSD11B1 (0.52) | HSD11B1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL5081813 | 0.83 | SMN1; SMN2 (0.68) | HSD11B1ALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL5078675 | 0.83 | SMN1; SMN2 (0.68) | HSD11B1ALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL19248163 | 0.83 | HSD11B1 (1.00) | HSD11B1ALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL20672529 | 0.82 | HSD11B1 (0.60) | HSD11B1ALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL29318615 | 0.81 | HSD11B1 (0.56) | HSD11B1ALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL19173933 | 0.81 | HSD11B1 (0.56) | HSD11B1ALDH1A1SMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | ARISAN THERAPEUTICS INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-3405183-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | Arisan Therapeutics Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017127306-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | ARISAN THERAPEUTICS (US) | 2017-07-27 | — | — | WO | disclosed |
| WO-2017127306-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | ARISAN THERAPEUTICS (US) | 2017-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | IFNAR1, MEP1B, MEP1A | HSD11B1 1438/4885ALDH1A1 652/4885SMN1; SMN2 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.